COVID-19 Therapeutics Information

Registration for COVID-19 monoclonal antibody therapeutics are not available in Broward Health’s emergency rooms and are by appointment only. To schedule an appointment for monoclonal antibody treatment or prevention for COVID-19, you must:

  • Have an order from a primary care physician
  • Meet the FDA Emergency Use Authorization criteria
  • Additional information on COVID-19 treatment and prevention is available on the Florida Department of Health COVID-19 response page. If you are experiencing a medical emergency, call 9-1-1 or visit the emergency room.

For more information and to verify eligibility, call Broward Health Nurse Connect line 7 days a week from 7 am – 10 pm to speak with a registered nurse: 954-320-5730.

NURSE CONNECT - OUR CARING AND EXPERIENCED REGISTERED NURSES OFFER:

  • Free nursing advice provided 7 days a week
  • Guidance on how to manage your symptoms
  • Assistance with the proper medication protocol
  • Assistance with finding a physician & scheduling urgent appointments
COVID clinical trials

For patients infected with COVID-19 experiencing mild to moderate symptoms and meet the following criteria for the treatment option

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg):

  • With positive results of direct SARS-CoV-2 viral testing, and
  • Who are at high risk for progression to severe COVID-19, including hospitalization or death, and
  • For whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. (14.4)
  • Bebtelovimab is currently authorized in all U.S. regions until further notice by the Agency.

    Please review the Bebtelovimab EUA, order form, and letter to ordering physicians, PA’s and APRNs who are not credentialed at Broward Health.

cardiac cta image

For patients who do not have COVID-19 and meet the following criteria for the preventative option

Evusheld (tixagevimab co-packaged with cilgavimab) for emergency use as pre-exposure prophylaxis for prevention of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

  • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
  • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

Please review the Evusheld (tixagevimab co-packaged with cilgavimab) EUA, order form, and letter to ordering physicians, PA’s and APRNs who are not credentialed at Broward Health.